Euronews Debates | How can Europe shape the future of biosimilar medicines? - Euronews

With the outgo of healthcare successful Europe spiralling, experts are considering however we tin physique the sustainable healthcare strategy of the future.

Currently, astir a 3rd of healthcare spending goes towards biologic medicines - drugs that usage surviving organisms arsenic ingredients. These medicines people parts of your immune strategy to dainty disease, and are particularly effectual for the attraction of illnesses specified arsenic arthritis.

But portion they are effective, and successful ever-growing demand, they are costly. IQVIA, a biopharmaceutical company, recovered biologics accounted for 34 per cent of medicine spending successful Europe successful 2021, astatine a full outgo of €78.6 billion.

With healthcare systems nether expanding fiscal strain, particularly successful the aftermath of the COVID-19 pandemic, much cost-effective alternatives could beryllium seen arsenic welcome.

Biosimilar drugs are highly akin to biologic medicines successful presumption of structure, biologic activity, and efficacy, but they are vastly cheaper to develop. This is due to the fact that they are often developed based connected a palmy biologic cause erstwhile its patent has expired.

For example, successful 2017 the NHS successful England saved £324 cardinal (€373 million) by switching from utilizing 10 costly medicines to biosimilars and generics.

But, crossed Europe, their take-up is patchy.

Euronews is gathering a sheet of experts, manufacture leaders and cardinal players successful Brussels to sermon the challenges astir creating a sustainable biosimilar marketplace system.

On November 15, from 1530 CET, our unrecorded panel, astatine the European Parliament, volition sermon cardinal questions specified as:

• What forces are shaping the biosimilar medicines marketplace successful Europe?

• What is presently being done and what needs to beryllium addressed successful the aboriginal to make a uniform, sustainable system?

• Why has determination been a dilatory take-up of biosimilars successful immoderate countries?

• What does it each mean for patients and Europe’s healthcare systems arsenic a whole?

Our adept panellists volition dwell of:

• Tomislav Sokol, MEP, Group of the European People's Party & Member of the EU's Special Committee connected the COVID-19 Pandemic: lessons learned and recommendations for the future
• Adrian van den Hoven, Director General, Medicines for Europe
• Ian Henshaw, Global Head of Biosimilars, Biogen
• Luisa Avedano, Chief Executive Officer, European Federation of Crohn’s & Ulcerative Colitis Associations

The statement volition instrumentality spot during Global Biosimilars Week. It is the 3rd yearly societal media run encouraging radical to stock their stories, resources and accusation connected societal media with the hashtag #GlobalBiosimilarsWeek.

Ask your questions, articulation the debate, and fto america cognize what you think. Our guests are acceptable to answer!